To investigate the potential for a QT/QTc study in Japan, a randomized, single-blind, crossover study was conducted using moxifloxacin in 64 healthy Japanese male volunteers. A 12-lead Holter electrocardiogram was used to test a relatively small population at each of 4 incorporated clinical research units to confirm the assay sensitivity and efficiency. Moxifloxacin (400 mg) significantly prolonged QT intervals, as previously reported, with small variations in this study. In addition, the placebo-adjusted mean QTcF changes from predose baseline showed that the lower bounds of the 1-sided 95% confidence interval exceeded 5 milliseconds at all of the clinical research units. The data also indicated statistically significant concentration-QT relationships in 3 of the 4 research units by separate analysis. These findings and the small amount of variability in this study suggest the feasibility of conducting a high-quality QT/QTc study in Japan.
BelardinelliLAntzelevitchCVosMA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24(12):619–625.
2.
ShahRR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundam Clin Pharmacol. 2002;16(2):147–156.
3.
ShahRR. Drug-induced prolongation of the QT interval: why the regulatory concern?Fundam Clin Pharmacol. 2002;16(2):119–124.
DarpoBAginMKazieradDJ. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?J Clin Pharmacol. 2006;46(6):598–612.
6.
MalikMGarnettCZhangJ. Through QT studies: questions and quandaries. Drug Saf. 2010;33(1):1–14.
7.
BadiliniFMaison-BlanchePChildersRCoumelP. QT interval analysis on ambulatory electrocardiogram recordings: a selective beat averaging approach. Med Biol Eng Comput. 1999;37(1):71–79.
8.
StassHDalhoffAKubitzaDSchühlyU. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998;42(8):2060–2065.
9.
FridericiaLS. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand. 1920;53:469–486.
10.
BazettHC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353–370.
11.
StassHKubitzaD. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(suppl B):83–90.
12.
GrosjeanPUrienS, Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval. J Clin Pharmacol. 2012;52(3):329–338.
13.
CrumbWCaveroI. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technolo Today. 1999;2(7):270–280.
14.
SarapaNMorganrothJCoudercJP. Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. Ann Noninvasive Electrocardiol. 2004;9(1):48–57.
15.
AhnveSVallinH. Influence of heart rate and inhibition of autonomic tone on the QT interval. Circulation. 1982;65:435–439.
16.
SagieALarsonMGoldbergRBengtsonJLevyD. An improved method for adjusting the QT interval for heart rate (the Framingham heart study). Am J Cardiol. 1992;70:797–801.
17.
MalikM. Problem of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2003;12(4):411–420.
18.
DesaiMLiLDestaZMalikMFlockhartD. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmcol. 2003;55(6):511–517.
19.
De PontiFPoluzziEMontanaroN. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000;56:1–18.
20.
ZhangJMachadoG. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat. 2008;18(3):451–467.
21.
DarpoBNeboutTSagerP. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline. J Clin Pharmacol. 2006;46(5):498–507.
22.
DamleBLabadieRRCuozzoC. Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation. Antimicrob Agents Chemother. 2011;55(9):4302–4307.
23.
SarapaNBrittoMR. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf. 2008;7(3):305–318.
24.
GarnettCEBeasleyNBhattaramA. Concentration-QT relationship plays a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48(1):13–18.
25.
EvertSLiuXKWoosleyRL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 2009;7(5):547–557.
